Trial · NCT07481383
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
NCT07481383, Phase 1, Recruiting, Continuity Biosciences, LLC
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer. Trials, record NCT07481383. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07481383
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
- NCT number
- NCT07481383
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Continuity Biosciences, LLC
- Conditions
- Pancreatic Adenocarcinoma Non-resectable
- Interventions
- ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
- First posted
- 2026-03-18
- Last updated
- 2026-07-06
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety, Tolerability, and Maximum Tolerated Delivered Dose as Assessed by Adverse Event Reporting | Screening through Week 20 | Incidence of adverse events (AEs), serious adverse events (SAEs), drug- or device-related AEs, and dose-limiting toxicities (DLTs) |
| Primary | Safety, Tolerability, and Maximum Tolerated Delivered Dose as Assessed by Adverse Event Reporting | Screening through Week 20 | Incidence of clinically significant abnormalities in physical examinations |
| Primary | Safety, Tolerability, and Maximum Tolerated Delivered Dose as Assessed by Adverse Event Reporting | Screening through Week 20 | Incidence of clinically significant abnormalities in vital signs |
| Primary | Safety, Tolerability, and Maximum Tolerated Delivered Dose as Assessed by Adverse Event Reporting | Screening through Week 20 | Incidence of clinically significant abnormalities in clinical laboratory tests (clinical chemistry, hematology, urinalysis) |
| Primary | Safety, Tolerability, and Maximum Tolerated Delivered Dose as Assessed by Adverse Event Reporting | Screening through Week 20 | Incidence of clinically significant abnormalities in 12-lead electrocardiograms (ECGs) |
| Secondary | Plasma Pharmacokinetic (PK) Concentrations Assessed by Plasma PK of Gemcitabine Pre- and Post-dose | Screening through Week 8 | Plasma PK of gemcitabine pre- and post-dose as measured by Cmax |
| Secondary | Plasma Pharmacokinetic (PK) Concentrations Assessed by Plasma PK of Gemcitabine Pre- and Post-dose | Screening through Week 8 | Plasma PK of gemcitabine pre- and post-dose as measured by tmax |
| Secondary | Plasma Pharmacokinetic (PK) Concentrations Assessed by Plasma PK of Gemcitabine Pre- and Post-dose | Screening through Week 8 | Plasma PK of gemcitabine pre- and post-dose as measured by t1/2 |
| Secondary | Plasma Pharmacokinetic (PK) Concentrations Assessed by Plasma PK of Gemcitabine Pre- and Post-dose | Screening through Week 8 | Plasma PK of gemcitabine pre- and post-dose as measured by Vd |
| Secondary | Plasma Pharmacokinetic (PK) Concentrations Assessed by Plasma PK of Gemcitabine Pre- and Post-dose | Screening through Week 8 | Plasma PK of gemcitabine pre- and post-dose as measured by AUC0-∞ |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07481383
GET https://conductscience.org/api/trials/v1/NCT07481383/registered